BMO Capital Markets Reiterates “$65.00” Price Target for Merck & Co., Inc. (MRK)

Merck & Co., Inc. (NYSE:MRK) received a $65.00 target price from stock analysts at BMO Capital Markets in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. BMO Capital Markets’ price target points to a potential upside of 19.27% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Barclays raised Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $62.00 to $64.00 in a report on Thursday. Leerink Swann decreased their price target on Merck & Co., Inc. from $67.00 to $66.00 and set a “market perform” rating for the company in a research note on Wednesday, February 14th. Credit Suisse Group decreased their price target on Merck & Co., Inc. from $67.00 to $66.00 and set an “outperform” rating for the company in a research note on Monday, February 5th. ValuEngine cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley increased their price target on Merck & Co., Inc. from $60.00 to $63.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $66.47.

How to Become a New Pot Stock Millionaire

Shares of NYSE:MRK traded down $0.03 during trading on Friday, reaching $54.50. 741,395 shares of the company traded hands, compared to its average volume of 12,797,021. The company has a market cap of $147,050.20, a price-to-earnings ratio of 13.63, a PEG ratio of 2.30 and a beta of 0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.06 and a current ratio of 1.33. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $66.41.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 2nd. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The company had revenue of $10.43 billion during the quarter, compared to analysts’ expectations of $10.48 billion. During the same quarter in the previous year, the firm earned $0.89 EPS. Merck & Co., Inc.’s revenue was up 3.1% on a year-over-year basis. research analysts predict that Merck & Co., Inc. will post 4.16 EPS for the current fiscal year.

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 5,000 shares of the stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $58.00, for a total value of $290,000.00. Following the transaction, the insider now owns 101,484 shares in the company, valued at $5,886,072. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the completion of the transaction, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,500 shares of company stock worth $5,026,025. Corporate insiders own 0.25% of the company’s stock.

Large investors have recently made changes to their positions in the business. Santori & Peters Inc. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $110,000. NewSquare Capital LLC increased its position in shares of Merck & Co., Inc. by 728.3% during the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock valued at $115,000 after acquiring an additional 13,014 shares during the last quarter. Stevens First Principles Investment Advisors increased its position in shares of Merck & Co., Inc. by 79.3% during the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock valued at $117,000 after acquiring an additional 920 shares during the last quarter. Avestar Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $130,000. Finally, Balentine LLC increased its position in shares of Merck & Co., Inc. by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 74.63% of the company’s stock.

WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3334995/bmo-capital-markets-reiterates-65-00-price-target-for-merck-co-inc-mrk.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Limelight Networks  Sees Large Volume Increase After Earnings Beat
Limelight Networks Sees Large Volume Increase After Earnings Beat
Skechers U.S.A.  Trading Down 27% Following Analyst Downgrade
Skechers U.S.A. Trading Down 27% Following Analyst Downgrade
Head to Head Comparison: DistributionNOW  and Its Competitors
Head to Head Comparison: DistributionNOW and Its Competitors
Head-To-Head Comparison: COBHAM  and BAE Systems
Head-To-Head Comparison: COBHAM and BAE Systems
Analysts Expect Alkermes Plc  Will Announce Earnings of -$0.08 Per Share
Analysts Expect Alkermes Plc Will Announce Earnings of -$0.08 Per Share
Contrasting Highwoods Properties  & Equity Residential
Contrasting Highwoods Properties & Equity Residential


© 2006-2018 Ticker Report. Google+.